Glaucoma

Host Hamza Shah, OD, MS, FAAO, is joined by Austin Lifferth, OD, FAAO, to discuss interventional glaucoma, spurred by Funke et al's paper, "Interventional glaucoma consensus treatment protocol."

Pathik Amin, OD, FAAO, gave a presentation to the optometry cohort at the conference on glaucoma management, focusing on surgical options and recent advancements.

This evidence-based eye care podcast seeks to turn research into practical clinical decisions, with new episodes on the first Monday of each month featuring expert guests across glaucoma, retina, dry eye, AI, and more.

Pathik P. Amin, OD, FAAO, details his segment of an educational track session on glaucoma at this year's conference.

The trial will evaluate the safety and effectiveness of the company's titratable glaucoma therapy system, designed to optimize IOP reduction in patients undergoing glaucoma surgery.

The study included 144 patients with glaucoma or ocular hypertension who underwent 24-hour IOP monitoring between October 2023 and April 2024.

In this podcast, experts Charles C. Wykoff, MD, PhD, FASRS; Jed H. Assam, MD, MS; Diana V. Do, MD; and Dante Pieramici, MD, FASRS; discuss the diagnosis, clinical features, and evolving management strategies for patients diagnosed with macular telangiectasia type 2.

In this podcast, experts Janelle L. Davison, OD; Cecelia Koetting, OD, FAAO, DipABO; and Cory J. Lappin, OD, MS, FAAO; discuss neuromodulation as a treatment modality for dry eye disease, focusing on a novel thermoregulatory therapy.

In this podcast, expert Mile Brujic, OD, FAAO, discusses the burden, diagnosis, and management of Demodex blepharitis, highlighting a recently approved targeted treatment option.

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Benjamin P. Casella, OD, FAAO, shares perspectives on the most impactful glaucoma developments from the past year and the future role of interventional and personalized care.

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

New clinical data and trial updates closed out 2025.

A recent study represents a step forward in investigations of the retinal layers as they are affected by glaucoma.

The researchers conducted a literature search of MEDLINE and Embase, PubMed, Cochrane Library, and Web of Sciences databases from 2003 to 2023.

Justin Schweitzer, OD, outlines the intricacies of glaucoma care with 3 cases.

The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, exposure duration, and thermal spread in a simulated ciliary body using computer modeling.

NCX 470 is Nicox’s lead dual-mechanism bimatoprost eye drop for lowering IOP in open-angle glaucoma or ocular hypertension.

Wen, OD, gives an overview of the glaucoma landscape, from necessary technology and management options.

A shift toward minimally invasive, evidence-based interventions is redefining standards of care.

Locking in correct prescriptions is as easy as checking a box.

The vital role of dialogue and education in managing glaucoma.

The “chip-on-eye” platform works by mimicking the flow of ocular fluids through the endothelial wall.